<DOC>
	<DOCNO>NCT00503152</DOCNO>
	<brief_summary>In people type 2 diabetes , microalbuminuria strong , independent risk factor diabetic nephropathy cardiovascular morbidity mortality . ACE inhibitor therapy decrease risk microalbuminuria hypertensive subject type 2 diabetes normoalbuminuria 40 % . Available data suggest angiotensin II receptor blocker ( ARBs ) might similar renoprotective effect effect might increase combined ACE inhibitor therapy . The study evaluate effect , similar blood pressure control ( systolic/diastolic &lt; 130/80 mmHg ) , period three year , dual renin-angiotensin-system ( RAS ) blockade benazepril valsartan combination therapy compare single RAS blockade benazepril valsartan alone microalbuminuria cardiovascular event high-risk patient type 2 diabetes , creatinine &lt; 1.5 mg/dl , evidence microalbuminuria high risk renal disease , hypertension urinary albumin excretion 7 19 microgram/min . The relationship albuminuria cardiovascular outcome also evaluate . The study expect show effective prevention microalbuminuria cardiovascular event combine single drug ACE inhibitor ARB therapy . As compare ACE inhibitor , ARB therapy expect similar effect microalbuminuria , inferior cardioprotective effect . Applied clinical practice , finding help prevent renal cardiovascular complication , related treatment cost , type 2 diabetes .</brief_summary>
	<brief_title>Preventing Microalbuminuria Type 2 Diabetes</brief_title>
	<detailed_description>Nephropathy type 2 diabetes lead cause end stage renal disease ( ESRD ) world.According World Health Organization ( WHO ) , diabetes affect 170 million people , , due progressive age population , life-style modification increase burden obesity , number expect rise 370 million 2030 . About one third affect eventually progressive deterioration renal function Untreated , patient progress ESRD within 10 year die prematurely cardiovascular complication ( 10-fold frequent diabetic nephropathy without general population ) . Costs renal replacement therapy patient - treatment related complication - also progressively increase . Persistent microalbuminuria first clinical sign renal dysfunction diabetic patient progress overt proteinuria 20 40 percent case . In 10 50 percent patient proteinuria , chronic kidney disease develop ultimately require dialysis transplantation . Of great concern , 40 50 percent type 2 diabetic patient microalbuminuria eventually die cardiovascular disease.Thus , prevent ( delay ) development microalbuminuria key treatment goal renoprotection , possibly , cardioprotection . A large scale randomize trial , BErgamo NEphrologic DIabetes Complications Trial ( BENEDICT ) find treatment ACE-inhibitor trandolapril ( either alone combined calcium channel blocker verapamil ) significantly reduce incidence microalbuminuria 1204 patient type 2 diabetes hypertension , normal urinary albumin excretion , compare placebo . The effect prevent microalbuminuria exceed expectation base change blood pressure alone enhance combined calcium channel blocker therapy . Studies patient type 2 diabetes micro- macro- albuminuria clearly show ARBs renoprotective effect trial evaluate effect angiotensin receptor blocker ( ARBs ) incidence microalbuminuria type 2 diabetic patient normal urinary albumin excretion rate miss . Whether beneficial effect development microalbuminuria enhance ACE inhibitor ARBs give combination establish far . However , find combined ACE inhibitor ARB therapy effectively single drug RAS blockade reduce albuminuria proteinuria subject type 2 diabetes slow progression ESRD non-diabetic chronic nephropathy , suggest renoprotective effect combine therapy could superior single drug blockade RAS also diabetic patient evidence renal disease . Post hoc analyse BENEDICT trial find high-normal albuminuria baseline evaluation ( defined urinary albumin excretion rate 10 µg/min upper limit study entry : 19 µg/min ) strong baseline predictor subsequent development microalbuminuria . Indeed , regardless treatment randomization , 69 271 ( 25.5 % ) patient high-normal albuminuria ( urinary albumin excretion &gt; 10µg/min ) progress end point compare 32 933 ( 3.4 % ) low-normal albuminuria ( &lt; 10 % ) . Thus , large-part excess risk microalbuminuria observe people type 2 diabetes associate high-normal albuminuria . In addition , clinical trial might clinical relevance Italian National Health service ( SSN ) : apply clinical practice result help reduce renal cardiovascular complication related treatment cost , type 2 diabetes . Aims Primary To evaluate whether , comparable blood pressure control , dual RAS blockade combine therapy halve dos benazepril ( 10 mg/day ) valsartan ( 160 mg/day ) reduce incidence microalbuminuria effectively single drug RAS blockade full dos benazepril ( 20 mg/day ) give alone high-risk patient type 2 diabetes , hypertension high normal albuminuria . Secondary - To evaluate whether , comparable blood pressure control , dual RAS blockade combine therapy halve dos benazepril ( 10 mg/day ) valsartan ( 160 mg/day ) reduce incidence microalbuminuria effectively valsartan ( 320 mg/day ) give alone high-risk patient type 2 diabetes , hypertension high normal albuminuria . - To evaluate whether , comparable blood pressure control , effect benazepril valsartan therapy similar whether , alternatively , one two treatment offer superior protective effect development microalbuminuria study population . - To evaluate effect three study treatment incidence fatal non-fatal cardiovascular event , regression low-normal albuminuria ( urinary albumin excretion &lt; 7 µg/min ) , albuminuria ( consider continuous variable ) , serum creatinine , lipid profile , GFR ( representative subgroup ) ; - To assess relationship , study group whole within treatment group , renal outcome variable ( include microalbuminuria time-dependent change albuminuria ) fatal non-fatal cardiovascular event , achieve blood pressure metabolic control renal and/or cardiovascular outcome variable achieve albuminuria reduction residual follow-up albuminuria renal and/or cardiovascular outcome variable . Design This multicenter , Prospective , Randomized , Open label , Blinded End point ( PROBE ) trial 3-year treatment halve dos benazepril ( 10 mg/day ) valsartan ( 160 mg/day ) give combination , full dos benazepril ( 20 mg/day ) , valsartan ( 320 mg/day ) give alone 1020 consent patient &gt; 40 year old , type 2 diabetes ( WHO criteria ) , serum creatinine &lt; 1.5 mg/dl , high-normal albuminuria ( UAE &gt; 7 &lt; 20 µg/min least 2 3 overnight urine collection ) , specific contraindication study drug . Primary outcome variable microalbuminuria ( UAE &gt; 20µg /min least 2 3 overnight urine collection two consecutive visit 2 month apart ) primary comparison combine benazepril plus valsartan benazepril alone group . The analysis 80 % power detect ( p=0.05 , two-side test ) 40 % difference incidence microalbuminuria .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Males female &gt; 40 year old ; Highrisk subject type 2 diabetes ( WHO criteria ) ; History diabetes exceed 25 year ; High blood pressure ( systolic and/or diastolic blood pressure &gt; 135/85 mmHg concomitant treatment blood pressure lower medication ) ; Serum creatinine concentration &lt; 1.5 mg/dl ; Overnight urinary albumin excretion ( least 2 3 consecutive overnight urine collection ) &gt; 7 &lt; 20 µg/min ; Legal capacity ; Written inform consent . Uncontrolled diabetes ( glycated hemoglobin &gt; 11 % ) ; Specific contraindication history hypersensitivity study drug ; Serum potassium ≥ 5.5 mEq/L despite diuretic therapy , optimize metabolic acid/base control ; Bilateral renal artery stenosis ; Previous history allergy intolerance , evidence immunologicallymediated renal disease , systemic disease , cancer ; Drug alcohol abuse ; Any chronic clinical condition may affect completion trial confound data interpretation ; Pregnancy lactating ; Women childbearing potential without follow scientifically accept form contraception ; Legal incapacity and/or circumstance render patient unable understand nature , scope possible consequence trial ; Evidence uncooperative attitude ; Any evidence patient able complete trial followup .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>